sgusers的部落格

來源 : 統計暨普查局根據統計暨普查局資料顯示，文件倉2012年有營運的批發及零售店舖有10,930間、街市攤檔及固定街檔共1,703間，按年分別減少32間及72間。2012年底的在職員工合計51,817人，按年增加7,266人。總收益達864.1億元（澳門元，下同），總支出為783.6億元，均按年上升28%。反映行業對經濟貢獻的增加值總額上升21%，為173.9億元；固定資本形成總額為17億元，增加104%。按行業分析，經營車輛及車用燃料銷售業店舖有900間，按年增加38間，在職員工有3,641人，增加744人。行業收益上升23%，達61.8億元；其中，豪華汽車需求增加，令機動車銷售收益上升30%，為39.7億元；車用燃料零售收益為13.5億元，增加11%。行業支出為58.4億元，上升20%；增加值總額有9.4億元，升幅達66%。固定資本形成總額為3,531萬元，按年減少30%。經營批發業店舖為4,033間，按年減少300間，在職員工共15,265人，增加739人。行業收益上升17%，為252.7億元；其中，糧食、飲品及煙草批存倉(79.5億元)和電器、藥物和衛生及清潔用品等消費品批發(64.6億元)分別佔總數31%及26%。行業支出增加15%，為241.3億元；增加值總額及固定資本形成總額分別為32.7億元及1.8億元，升幅分別為14%及9%。經營零售業店舖有5,997間，按年增加230間，在職員工共29,979人，增加5,833人。受惠於旅客購物消費持續增長及內部需求擴大，行業收益按年上升34%，達533.1億元；其中，鐘錶及金飾零售(162.9億元)和百貨零售(88.2億元)分別佔總數31%及17%。行業支出為470.1億元，上升37%，主要是購貨成本增加所致；增加值總額為128.7億元，增加21%。固定資本形成總額按年急升141%，達14.8億元，主因是購買商舖及大型裝修工程增加。2012年有營運的街市攤檔(757間)及固定街檔(946間)合共1,703間，按年減少72間；在職員工有2,932人，有薪酬員工只有448人。街市攤檔及固定街檔的收益(16.4億元)及支出(13.8億元)按年分別上升24%和26%；增加值總額為3.1億元，增加18%。儲存

即日-1/1/2014 百萬水晶聖誕 邀請本港首批原型師及情景模型創作大師黃偉麟，迷你倉以逾百萬顆的水晶珠打造 19 世紀維多利亞時代的聖誕大餐及家居布置，瑰麗絢燦，並於聖誕節期間，有聖誕老人及女郎於場內表演雜耍，大派聖誕糖果。 •地點：東涌東薈城•時間：雜耍表演 12月 21 至 22 日及 25 至 26 日 2pm-2:45pm / 4pm-4:45pm•查詢：2109 2933 20、21、23、24/12 冰上聖誕騷 聖誕商場表演特別多，又一城歡天雪地將舉行冰上舞動聖誕匯演，逾百位花式溜冰學員以傳統聖誕為主題，編排一系列優美而高難度的花式溜冰表演。另聖誕老人與聖誕女郎將於 12 月 22 至 25 日隨時於冰面出現，送上聖誕糖果和大家一起拍照留念。 •地點︰九龍塘又一城 UG 又一城歡天雪地•時間︰7pm•查詢︰2844 3588 即日-30/1/2014 不如，我�由頭�過何博欣以王家衛導演的《春光乍洩》內一句經典對白「不如，我�由頭�過」，重新演繹，讓平凡的都市人搖身一變，成為各自生活中的主角，如正在茶餐廳享受奶茶的老人家、早上赤裸上身躺在地上的地盤工人……•地點：柴灣嘉業街 18 號明報工業中心 A座 10 樓 Artify Gallery•時間：星期二至五 10am-7pm，星期六 10am-7pm，星期日及星期一休息•查詢：3543 1260 即日-2/1/2014 聖誕日玩夜探天際 100 只需購買一張正價門票，即可於日間及晚間各入場一次，體驗日夜不同的天際聖誕。日間有「飛越香港 3D 聖誕」及與聖誕老人合照；而夜間則可在維港上空一起尋找天際星座。而周末及公眾假期還會舉辦「天際聖誕玩藝坊」，與大家歡度佳節。 •地點：九龍站環球貿易廣場 100 樓天際 100 香港觀景台•時間：10am-9pm（最後進場 8pm）•門票：成人 $168，小童 / 長者$118，學生 $134 20/12-26/1/2014 我係小忌廉 POP-UP STORE Encore 當年是各大小朋友心目中的女神─小忌廉，再次訪港！POP-UP STORE 除多款日本空運到港精品，更有特別設計的香港限定小忌廉造型商品，值得收藏！店內還有以《我係小忌廉》為主題的彩虹攤位遊戲及夾公仔機，一眾 70 後朋友不容錯過！ •地點：銅鑼灣世貿中心 6 樓全層•時間：10am-11:45pm 即日-21/3/2014 Sony 大抽獎 贏 FIFA 世盃門票 凡購買指定 Sony 產品即可參加大抽獎，四回合抽獎共有 8 位幸運兒可贏取 2014 年 FIFA 世界盃決賽入場�兩張、雙人來回香港巴西里約熱內盧經濟客位機票及 4 晚雙人酒店住宿；顧客選購每件產品的價值愈高，獲抽獎機會就更多。（指定 Sony 產品請上網查詢）•查詢：2345 2966/ .sony.com.hk/fifa2014 19- 23/12 原塑 人說愛情魔力大，人為了愛可改變外觀與內在。美國編劇 Neil Labute 寫美麗碩士生改造平平無奇男子的愛情習作，殺傷力駭人。薛海暉、張學良及陳�沁組成方外無式的創團演出。 •地點：九龍城兆基創意書院•時間：12 月 19 至 21、23 日，7:30pm，12 月 21 日 2:30pm，12 月 22 日 12nn 及 4pm•門票：$200•查詢：9272 5207 即日-3-1/2014 SWAROVSKI 聖誕樹 閃亮機場 一棵近 15 米高的 Swarovski 聖誕樹現豎立在香港國際機場，它由接機大堂一直延伸至離港大堂，非常壯觀，樹身用上過百萬顆奧地利 Swarovski 水晶打造而成，設計時尚又富大都會節日氣氛。設互動拍照專區，與親友留下開心回憶！ •地點：香港國際機場 即日-23/12、2-20/1/2014 卡夫卡在布拉格 適逢卡夫卡誕生 130 周年，觀眾可透過圖片、文獻、小說與錄影了解這位在美麗城市布拉格出生，以德語創作的作家生平和作品。專門研究卡夫卡的李歐藩教授將於展覽最後一天晚上 7 時主持免費講座，門票先到先得。 •地點：灣仔香港歌德學院•費用：免費•查詢：2802 0088 即日-12/1 當代視覺藝術展 韓國藝術家李庸白的《破鏡》以液晶屏幕、雙向玻璃、碎裂聲效，讓觀眾自我對話，展現科技結合藝術的力量。香港藝術中心第五屆旗艦視藝展，廣邀包括他在內的亞洲藝術家探索科技啟發藝術。 •地點：灣仔香港藝術中心•費用：免費•查詢：2582 0200 18-22/12 投選！最想睇旅遊計劃 看《三個小生去旅行》，四哥去邊我們無得選，頂多覺得佢帶《U Magazine》旅遊天書有品味，今次就唔同喇！M21 舉辦的「非常旅人任務」，首季以「保衛地球」為題，公開徵集同環保或地球保育有關的旅遊計劃，獲選的項目最高可獲港幣 $80,000 元資助，幫人圓夢之餘，尚有 M21 隨團攝製隊將旅程拍成紀錄，同觀眾分享。最重要，是可以一人一票，投選你最想睇的旅遊計劃。 非常旅人任務 13-22/12 新界無戰事 滿道編劇，張秉權執導，五位演員分飾二十多個角色，加入南音與客家山歌，回到十九世紀末新界北區鄉民對抗英軍捍衛家園的不為人知歷史一頁。致群劇社、香港戲劇工程辦合製作。 •地點：上水山區大會堂•時間：12 月 13 日、19 日 4pm 12 月 14、15 及 21 日 3pm、8pm，12 月 22 日 3pm•門票：$120•查詢：amitydrama2009@yahoo.com.hk 即日-1/1/2014 聖誕獻良機大抽獎 使用電子貨幣於 6 大商場內指定商舖即日單一消費滿 $100 或以上，即可換領「聖誕獻良機大抽獎」抽獎券一張；即日單一消費滿 $200 或以上則可換領 2 張；如此類推，每次即日單一消費最多可換領抽獎券 10 張。有機會贏取 Samsung Note 3 一部。得獎名額10名。 •地點：杏花新城東翼一樓推廣活動攤位 、綠楊坊二樓推廣活動攤位、連理街推廣活動攤位、Citylink 推廣活動攤位、海趣坊推廣活動攤位、駿景廣場顧客服務中心 •換領抽獎券日期：逢星期六、日及公眾假期 12nn-10pm text︱Helen、Ami edit︱Helen art︱K 即日-29/12 藝緣畫會 活化牛棚 展示 17 位藝術家作品包括繪畫、數碼電腦版畫、雕塑、裝置藝術等，更設「每人都是小畫家」工作坊，參加者可透過電腦中的小畫家創作數碼版畫，即時打印，與創會會長陳餘生作品並列展出，組成大型拼貼圖。•地點：馬頭角道 63 號牛棚藝術村 12 號單位；牛棚藝術村 8 號單位 (工作坊) 21-25/12 高蹺王巡遊表演 香港鮮有欣賞到踩高蹺表演，9 位參加了首屆「香港高蹺王」比賽而進入決賽的參加者，將於聖誕期間，在香港多處打自存倉成家傳戶曉的角色為主題造型，進行巡遊表演拉票，而大家更可以於 facebook 投票，選出首屆「高蹺王」！•地點：尖東百週年紀念花園、尖沙咀中心及帝國中心•時間：7:30pm-9:30pm，網上投票 即日至 1 月 1 日•查詢：2369 6662 tsimshatsuicentre 即日-5/1/2014 推出聖誕戲偶劇場 香港迪士尼樂園的「反斗奇兵大本營」、「灰熊山谷」及「迷離莊園」現每日上演溫馨小故事：如「反斗玩偶劇場」就設互動環節，大家可以參與演繹當中角色；而「灰熊手偶劇場」就訴說熊寶寶的冬日心願；還有「亨利爵士皮影劇場」的奇異故事，令大家樂在其中。 hongkongdisneyland 12-15、18-20 及 26/12 奇幻魅影魔術表演 又一城除了有充滿�芬蘭聖誕氣氛的聖老人村落，周末期間更有一連串精采表演；其中有由澳洲國際魔術大師 John Taylor 呈獻的「奇幻魅影魔術表演」，他的拿手絕活將一一呈現大家眼前，萬勿錯過！ •地點：又一城經典聖誕舞台 LG2 層•時間：12 月 14、15、及 20 至 26 日 5pm-6pm，12 月 12、13、18 及 19 日 7pm-8pm•查詢：2844 2223 14/12-1/1/2014 樂天小熊 現身昂坪市集 超過 100 款可愛造型的樂天小熊，現遍布東涌纜車站及昂坪市集每個角落，市集內更有多個以樂天小熊為主題的布置場景，等大家影相留念；還有一個 6 呎高的樂天小熊將不定時出沒，向大家大派朱古力小熊餅。•地點：東涌纜車站及昂坪市集•查詢：3666 0606 np360hk 20/1 截止報名 無國界醫生野外定向 想親身體驗無國界醫生救援人員的艱辛和災區的種種限制，並更認識他們的工作，可參加無國界醫生野外定向，今次大會更將醫療設施和場景搬入賽事中心，參加者有機會看到前�手術室治療病人的緊急情況，並一嘗營養治療食品。•舉行日期：2014 年 3 月 9 日•地點：長洲•出發時間：9am 起•報名及查詢：.msf.hk/oc 或 2959 4249•備註：除設「精英組」及「公開組」外，亦有「體驗組」和「親子組」。 即日-29/12 賀聖誕禮品巡禮 有多款聖誕精品、布置飾品、派對禮品、時尚服飾、電子產品等，只需於店內購物滿 $300（折扣後）及出示上載於「香港．設計廊」Facebook專頁的優惠券，即送 O+ 胡椒鹽罌一個，數量有限，送完即止。•地點：灣仔港灣道1號香港會議展覽中心地下「香港．設計廊」•時間：10am-8:30pm•查詢：2584 4146 HKTDC.DesignGallery 12-15/12、19-22/12 細味•禮品薈 有多位本地設計師及社福機構在科學園內的 30 個攤位售賣創意精品及手工藝品；更設免費親子工作坊，導賞團「科學探索行」、彈彈床、扭氣球等，加埋園內中西餐廳提供的美食，滿足晒小朋友食、買、玩大個願望！•地點：科學園第二期浚湖樓地下•時間：11:30am-6pm•費用：免費•查詢：.hkstp.org / 2629 6837 即日-29/12 禮物轉贈大行動 聖誕節是送禮及收禮的時候，但亦為每年造成了很多「禮餘」問題，不想浪費送贈者的心意，就將家中的積存及今年所收的剩餘禮物捐出，轉贈予有需要家庭，及於救世軍旗下 16 間家品店重新上架。•收集地點：將軍澳東港城一樓回收箱－顧客服務中心旁（港鐵坑口站 A1 出口）•時間：10am-10pm•募集四大「禮餘」：現金禮券、禦寒衣物、小型家電、益智玩具及書籍•查詢：2628 7399 即日-1/1/2014 「蠟筆小新」回顧展 商場除化身為「蠟筆小新鬼馬學園」，學園內還設「蠟筆小新」回顧展覽室，公開展出已故《蠟筆小新》作家臼井儀人之珍貴手稿，讓大家一睹《蠟筆小新》的誕生過程；還可欣賞到少爺占為小新及小白重新設計的服飾。•地點：愉景新城discoveryparkshoppingcentre 即日-1/1/2014 輕鬆小熊遊樂園 打造「輕鬆小熊 10 週年之星光遊樂園」，設夢幻迴旋木馬、香甜班戟派對及小熊演奏樂團場景布置，還有日本空運到港的巨型吹氣輕鬆小熊與大家揮揮手；輕鬆小熊更與 Korilakkuma小白熊舉行限定見面會，與 Fans 們見面擁抱。•地點：尖沙咀 The ONE UG 2 中庭•時間：10am-11pm，限定見面會 12 月 15、22、25 及 26 日 3pm 及 4pm•備註：見面會入場券將在活動舉行當日下午 1pm 免費派發，憑券入場可與兩小熊合照 1 張•查詢：3106 3640 即日-31/12 MegaBox 6 小時泊車優惠 於推廣期逢星一至四 5pm 後入閘及單一消費滿 $200 或以上即可享用 4 小時免費泊車服務，單一消費滿 $300 或以上即可享用 6 小時免費泊車服務。 •換領地點：九龍灣 MegaBox G 及 L9 顧客服務中心•時間：5pm-10:30pm（星期五、六、日及公眾假期除外）•查詢：2989 3000 14/12-2/2/2014 全城尋寶 贏比利時之旅 需到指定店舖與穿上由本地時裝設計系學生設計的特色服裝之「撒尿童子」銅像及一件比利時設計或產品合照，再「讚好」（Like）Facebook 專頁，並將照片上載至 Facebook 專頁。獲最多「讚好」的 8 張參賽照片，有關參加者將可競逐豐富獎品，包括比利時產品及三天比利時之旅。•參與店舖資料請上網查詢：.belgianspirit.be/ mannekenpishk reminder 20/12 暗中享用聖誕大餐 帶領大家體會不一樣的聖誕，推出「深『黑』聖誕 」奇妙之旅，參加者可體驗有多樣歐陸聖誕元素及創新感官效果，之後還可在晚宴廳摸黑品嘗有三道精美菜式的聖誕大餐，更有「暗」中表演、幸運大抽獎及交換禮物環節，雖然「看不見」卻令你暖在心窩。 dialogue-in-the-dark •地點：美孚景荔徑 8 號盈暉家居城 2 樓 215 室黑暗中對話體驗館•時間：聖誕大餐 6:15pm-9:30pm，•費用：$1,000 已包深『黑』聖誕之旅費用 （ 45 分鐘）•語言：雙語（廣東話及英語）•查詢：2891 0438 Start 即日起 Hello Kitty 八達通配飾形象百變的 Hello Kitty 永遠都係咁受歡迎，皆因無論男女老幼都係佢 Fans！八達通推出全新「Hello Kitty 八達通配飾」，有彩蝴蝶結及搖滾星星造型，成年版就附有銀鏈以作掛飾，而小童版就有頸繩，方便使用。 octopus hk •售賣地點：全� 7-Eleven 便利店及八達通網上商店•費用：每款 $178，不設按金及儲值額。•查詢：2266 2222 text、edit︱c art︱Keith 迷你倉

為增加企業競爭力，儲存財政部南區國稅局昨（13）日表示，企業招待經銷商及客戶的旅遊費用，因具獎勵性質，可由交際費改列為其他費用，並可按實際支出金額列帳，不受費用限額的申報限制。又到歲末年終，公司行號即將整理今年的帳證，南區國稅局昨天發出新聞稿，特別提醒公司行號注意今年度修正的課稅新規定。為協助企業拚經濟，財政部稍早已發佈解釋令，自今（102）年起，企業提供達一定業績標準的經銷商或客戶，具有獎勵性質的支出或佣金，准予列為企業的其他費用，並依所得稅法規定，列單申報主管稽徵機關，及填發免扣繳憑單給經銷商及客戶。過去企業招待經銷商或與業務有關的客戶出國旅遊，必須以交際費項目申報，且有金額上限；依據規定，一般企業的交迷你倉費，全年進貨額在3千萬以下者，須以全年進貨價的千分之1.5為限。為使課稅合理化，財政部也重新定義企業「交際費」的範圍，企業在營利活動過程中，為塑造或改進獲利環境、建立良好公共關係所支出的費用，即可認定為交際費。官員進一步解釋，交際費具有「任意支付」，以期待增加未來交易的目的，通常與營業收入之間，並無必然的因果關係。財政部表示，自今年起，企業如事先與經銷商或客戶約定，以達到一定購銷數量或金額，作為招待旅遊之條件者，可改列其他費用，以真實反映企業的經營利潤。不過，會計師提醒，財政部雖放寬獎勵旅遊的支出，可按實際支出金額列帳，但在實務上，稅捐機關常要求企業必須出具有受招待者簽名的單據，否則容易被國稅局剔除補稅。儲存倉

/NOT FOR DISTRIBUTION TO U.迷你倉S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW./TORONTO, Dec. 13, 2013 /CNW/ - Mercari Acquisition Corp. ("Mercari" NEX: MV.H) is pleased to announce that it, together with its wholly-owned subsidiary Mercari Subco Inc. ("Mercari Subco"), has entered into a definitive agreement dated December 13, 2013 (the "Amalgamation Agreement") pursuant to which Mercari Subco will amalgamate (the "Amalgamation") with Concordia Healthcare Inc. ("Concordia") to complete an arm's length qualifying transaction (the "Transaction") in accordance with the policies of the TSX Venture Exchange (the "TSXV"). The Amalgamation is structured as a three-cornered amalgamation and as a result the amalgamated corporation ("Amalco") will become a wholly-owned subsidiary of Mercari at the time of the completion of the Amalgamation. The Amalgamation Agreement will be made available on SEDAR at .sedar.com. Mercari has received conditional approval from the Toronto Stock Exchange (the "TSX") to have the common shares of the Resulting Issuer (as defined below) listed for trading on the TSX following the Transaction. Mercari anticipates closing the Transaction on or about December 20, 2013.About ConcordiaConcordia is an integrated healthcare company incorporated under the Business Corporations Act (Ontario) (the "OBCA") that targets three areas: (a) legacy pharmaceutical products; (b) specialized healthcare distribution that services the growing diabetic market; and (c) the acquisition and/or development of orphan drugs. These three business units are run as separate divisions but are inter-related. The cash-flow from legacy pharmaceuticals is used to fund operations and is also intended to fund the expansion of indications for potential orphan drugs. The specialized healthcare distribution division provides additional growth and cash-flow generation. Additionally, through its registered pharmacy operation this business is intended to provide a specialty distribution capability for orphan drugs once acquired and/or developed. All three of these divisions are operated through a corporate organization that provides executive leadership, industry experience, financial and capital markets experience, and an efficient tax structure. Concordia operates out of facilities in Oakville, Ontario, Kansas City, Missouri and Bridgetown, Barbados.Concordia's legacy pharmaceutical business was acquired in May 2013. Concordia's legacy pharmaceutical business includes the management and acquisition of legacy pharmaceutical products, both with patent life and exclusivity remaining (pre-legacy) and products that have reached full maturity but continue on a predictable revenue generation path, collectively referred to as legacy products.Concordia's existing portfolio of legacy drugs (the "Existing Portfolio") consists of Kapvay (clonidine extended release tablets), Ulesfia (benzyl alcohol) Lotion 5% and Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets).Concordia's specialized healthcare division (the "SHD Division") was acquired in October, 2013, with an effective date of August 1, 2013. The SHD Division is a United States national Internet and mail-order provider of diabetes testing supplies, pharmaceuticals, diabetic shoes, orthotic braces and other home medical equipment. The SHD Division operates primarily out of office and warehouse facilities located near Kansas City, Kansas.Concordia's orphan drugs division is intended to provide growth opportunities through the expansion into new indications for existing legacy products or the acquisition of approved orphan drugs and further expansion within their identified markets. In the initial execution of its orphan drug strategy Concordia, through its subsidiaries, entered into an agreement and plan of merger (the "Pinnacle Purchase Agreement") on November 8, 2013 to acquire Pinnacle Biologics, Inc. ("Pinnacle"). The legacy pharmaceutical product owned by Pinnacle has three oncology indications approved by the FDA and is being developed for the treatment of an additional rare form of cancer. Closing of the Pinnacle Purchase Agreement is not a pre-condition to completing the Amalgamation.Summary of Financial Information for ConcordiaThe following table sets forth selected consolidated financial information for Concordia as of and from the date of incorporation on December 5, 2012 to the period ended September 30, 2013. Concordia's first transaction was consummated on May 6, 2013. This information is derived from audited consolidated financial statements for the period ended September 30, 2013 prepared in accordance with International Financial Reporting Standards. All of the following information is reported in US dollars.US$For the period ended September 30, 2013Revenue $23,763,479Net Income 9,499,287Basic earnings per share 2.08Diluted earnings per share 1.63Total Assets 79,370,498Total Liabilities 59,727,063Proposed Concordia FinancingBefore the effective time of the Amalgamation, Concordia proposes to complete a private placement (the "Private Placement") of subscription receipts (the "Subscription Receipts"). Pursuant to the Private Placement, Concordia will offer up to CDN$30,000,000 of Subscription Receipts at a price of $6.25 per Subscription Receipt. Each Subscription Receipt will be exchangeable for one common share of Concordia. Pursuant to the terms of the Amalgamation Agreement, holders of Concordia common shares exchanged for the Subscription Receipts will receive common shares of Mercari upon completion of the Amalgamation (the "Resulting Issuer") on the basis of one Resulting Issuer common share for each Concordia common share held. The completion of the Private Placement is not a condition to closing the Transaction. In addition, Concordia has granted an option to the agents of the Private Placement (the "Agents") to purchase up to an additional 15% of the number of Subscription Receipts sold under the Private Placement on the same terms as under the Private Placement.The Agents will be entitled to receive a cash commission equal to 6% of the gross proceeds from the Private Placement (the "Agents' Commission") together with options (the "Agents' Compensation Options") entitling the Agents to subscribe for that number of common shares of Concordia as is equal to 4.0% of the total number of Concordia common shares issued pursuant to the exercise of Subscription Receipts under the Private Placement. Each Agents' Compensation Option will be exercisable to purchase one Concordia common share at the price of CDN$6.25 per common share for a period of 24 months from the date that the proceeds of the Private Placement are released from escrow in accordance with the terms of the Private Placement. The Agents' Compensation Options will be exchanged for Resulting Issuer Options, pursuant to the Amalgamation Agreement.It is anticipated that the net proceeds from the Private Placement will be used as follows:Gross proceeds from the Private Placement $30 millionAgents' Commission $1.8 millionTo be applied to Pinnacle acquisition $28.2 millionNotwithstanding the foregoing, management of Concordia and the Resulting Issuer may determine that it is in the best interests of Concordia or the Resulting Issuer to allocate the net proceeds of the Private Placement in a manner that is different than the foregoing and the net proceeds may be allocated accordingly. There may be circumstances, where for sound business reasons, the reallocation of funds may be necessary in order for the Resulting Issuer to achieve its stated business objectives.About the TransactionMercari will hold a special meeting of its shareholders on December 16, 2013 to approve, among other things, (i) a change in the name of Mercari from "Mercari Acquisition Corp." to "Concordia Healthcare Corp." or such other name as is agreed to by Concordia and Mercari; (ii) the appointment of the proposed directors for the Resulting Issuer; (iii) approval of a stock option plan for the Resulting Issuer; (iv) a consolidation of the common shares of Mercari on the basis of one (1) post-consolidation Mercari common share for every 48.08 pre-consolidation common shares of Mercari; and (v) and a change in Mercari's registered office address to the registered office address of Concordia. Details regarding the special meeting of the shareholders of Mercari are available in a management information circular dated November 11, 2013 that has been provided to shareholders of Mercari. In addition, the Amalgamation will be approved by the shareholders of Concordia by way of consent resolution prior to the Amalgamation.Pursuant to the terms of the warrant certificates representing the Concordia common share purchase warrants (the "Concordia Warrants"), the holders thereof may exercise the Concordia Warrants by delivering to Concordia prior to the date of the Amalgamation, a completed exercise form and payment of the aggregate sum of $1.00. It is intended that all of the issued and outstanding Concordia Warrants will be exercised in such manner prior to the Amalgamation.Under the terms of the Amalgamation Agreement, at the effective time of the Amalgamation, among other things:(a) each holder of Concordia common shares (except for Concordia common shares held by holders that have validly exercised their dissent rights in connection with the special resolution approving the Amalgamation) shall exchange their Concordia common shares for common shares of the Resulting Issuer instead of common shares of Amalco, on the basis of one (1) fully paid and non-assessable Resulting Issuer common share for every one (1) Concordia common share held; and(b) subject to receipt of all required regulatory approvals, each holder of options issued under Concordia's stock option plan (each a "Concordia Option") or Agents' Compensation Options outstanding immediately before the effective date of the Amalgamation shall exchange each such Concordia Option or Agents' Compensation Option, as the case may be, for one (1) option issued under the Resulting Issuer's stock option plan (each a "Resulting Issuer Option") with such Resulting Issuer Option having the same terms as the Concordia Option or Agent's Compensation Option, as the case may be, being exchanged, and each such Concordia Option or Agents' Compensation Option shall be cancelled. The exercise price for each Resulting Issuer common share underlying the Resulting Issuer Option will be equal to the exercise price per Concordia common share under the Concordia Option or the Agents' Compensation Option, as the case may be, in effect immediately prior to the Amalgamation on a post-consolidation basis.The completion of the Amalgamation is conditional on obtaining all necessary regulatory and shareholder approvals in connection with the matters described above and other conditions customary for a transaction of this type.Immediately after the completion of the Transaction, on a non-diluted basis and after giving effect to the Mercari consolidation, the shareholders of Mercari will own approximately 276,622 common shares of the Resulting Issuer and the shareholders of Concordia will own approximately 16,763,051 common shares of the Resulting Issuer (assuming 5,520,000 Subscription Receipts are issued pursuant to the Private Placement).Terei International Limited, a corporation incorporated under the laws of Hong Kong, will, after giving effect to the Transaction, beneficially own, control or direct, directly or indirectly, approximately 3,072,500 common shares of the Resulting Issuer, representing approximately 14.37% of the issued and outstanding common shares of the Resulting Issuer on a fully diluted basis. Mark Thompson, a resident of Toronto, Ontario, will, after giving effect to the Transaction, beneficially own, control or direct, directly or indirectly, approximately 2,398,750 common shares of the Resulting Issuer, representing approximately 11.22% of the issued and outstanding common shares of the Resulting Issuer on a fully diluted basis.Arm's Length TransactionThe Transaction is an arm's length transaction in accordance with the policies of the TSXV and is not subject to Mercari shar自存倉holder approval.Proposed Management and Board of Directors of the Resulting IssuerUpon completion of the Transaction, it is anticipated that the persons identified below will serve as directors and officers of the Resulting Issuer.Mark Thompson - Chief Executive Officer, President, DirectorMr. Thompson is the founder, CEO, President and a director of Concordia. He previously served as the former Senior Vice President and General Counsel of Legacy Pharma Limited Partnership and was a co-founder of Trimel Pharmaceuticals and Tribute Pharmaceuticals Inc. From 2002 to 2005, Mr. Thompson was employed by Biovail Corporation (currently Valeant), where he held the title of Vice-President, Business Development and, before that, Associate General Counsel. While at Biovail Corporation, Mr. Thompson was actively involved in mergers and acquisitions transactions valued at over $2 billion. Prior to joining Biovail Corporation, Mark was an associate at Osler, Hoskin and Harcourt LLP. Mark holds an H.BA, and MA from York University and an LL.B from the University of Ottawa.Leith Tessy - Chief Financial Officer, Secretary-TreasurerMr. Tessy has 25 years of international experience as a finance and operations executive. He has been successful driving mergers and acquisitions transactions (with total transaction value exceeding $1 billion), integrating acquired companies and expanding operating margins. Previous roles held include: CFO then COO of LG Nortel, a JV between Nortel Networks and LG Electronics based in Seoul, South Korea (under Mr. Tessy 's leadership, the company grew from approximately $500 million to approximately $1 billion, delivering 30% EBITDA margin), CFO of Nortel Networks' Global Carrier Networks group (at approximately $5 billion revenue, Nortel's largest, most profitable division), and SVP Finance at Nuance Communications (a highly acquisitive software company). Mr. Tessy holds an Industrial Engineering degree from University of Toronto and an MBA from Ivey School of Business, University of Western Ontario.John McCleery - Managing Director, Chief Financial Officer (of Concordia Pharmaceuticals Inc. and Concordia Laboratories Inc.)Mr. McCleery is the Managing Director and CFO of Concordia Pharmaceuticals Inc. and Concordia Laboratories Inc., which are subsidiaries of Concordia. He has 30 years of international experience as a senior financial and operational executive. He developed and managed the Enterprise Risk Management and Compliance program for Valeant Pharmaceuticals International Inc. (formerly Biovail Corporation), reporting company risks to the board of directors. Mr. McCleery chaired the Compliance Committee and the Canadian Investment (RSP; DPSP) Committee. Mr. McCleery served as Vice President and General Manager of Valeant Laboratories (Barbados) SRL (formerly Biovail Laboratories International SRL) the principal operating subsidiary where he had responsibility for managing intellectual property, treasury activities, research and development programs and business partner relationships with Merck, Johnson and Johnson, Wyeth, Forest and Teva etc. He was also a Director and Vice President, Treasurer of Valeant Insurance Incorporated (formerly Biovail Insurance Incorporated). Mr. McCleery served as Vice President, General Manager and Chief Financial Officer of Trimel BioPharma SRL and was responsible for all operational and financial management of the principal operating subsidiary of Trimel Pharmaceuticals Corporation. John is a Chartered Professional Accountant (CPA) and a Chartered Accountant (CA) having earned his designations with the Toronto office of PricewaterhouseCoopers.John Huss - DirectorAfter 20 years in the pharmaceutical and biotechnology industry, Mr. Huss founded H&P Labs Inc., a biotechnology company focused on early stages of drug development (Phase I & II) in humans. Before that Mr. Huss was President and CEO of Theratechnologies in Montreal. Since his return to Canada in 2010, he sits on the Board of BioQuebec and since 2012 he also serves on its Executive Committee, as Vice-President. Mr. Huss worked for sanofi from 1999 to 2010 in Germany, Canada, Switzerland and France. He joined sanofi in 1999 as a Business Unit Director for the German affiliate. In 2001, Mr. Huss joined the Canadian affiliate as Vice-President, Sales and Marketing in Toronto and moved to Montreal after the acquisition of Aventis. He became General Manager of the Swiss affiliate of sanofi-aventis in January 2007, based in Geneva. In August 2009, Mr. Huss joined the Head Office in Paris and worked next to the Chief Executive Officer, Chris Viehbacher, as Chief of Staff. Mr. Huss joined the pharmaceutical industry in 1990 and for 6 years performed various Sales and Marketing functions for Merck & Co. in the United States, Germany and Switzerland. In 1996, he was offered a position with F. Hoffman-La Roche as an Internal Product Manager at their Basel headquarters.Ron Schmeichel - Director, Non-Executive Chairman of the Board of DirectorsMr. Schmeichel has 18 years of experience in high-yield credit, leveraged loans, buy-outs and equity capital markets in Canada and the US. For the past 3 years, he has served as the President and CEO of Windsor Private Capital, a firm that manages both credit and private equity capital funds. The firm specializes in providing credit and equity lines for management buy-outs, recapitalizations, bridge and mezzanine loans and minority equity ownership to small/mid market United States and Canadian companies. Prior to this, Mr. Schmeichel was one of the founders and partners of JJR Capital Corp., a Toronto based merchant banking firm that specialized in reverse merger transactions on the TSXV. Since Concordia's inception, Mr. Schmeichel has served as the non-executive Chairman of the Concordia board of directors as well as a mergers and acquisitions advisor on six pharmaceutical/healthcare transactions, including the two foundational acquisitions that make up Concordia currently. Mr. Schmeichel has been on the board of over 15 venture-listed public companies and has served as a director and audit committee chair of one TSX-listed company. For the past 12 years, Mr. Schmeichel has been a guest lecturer at the University of Western Ontario, Faculty of Law, as well as the Ivey School of Business. He currently serves as a member of the Ontario Local Area Committee to the Toronto Stock Exchange-Venture Group. Mr. Schmeichel received a BA degree, with Merit, from York University in 1992 and a Juris Doctorate degree from the University of Western Ontario in 1995.Doug Deeth - DirectorMr. Deeth is a partner with the law firm of Deeth, Williams & Wall LLP. He is the former President of the Intellectual Property Law section of the Canadian Bar Association and has 25 years of experience in the pharmaceutical industry.Jordan Kupinsky - DirectorSince 2008, Mr. Kupinsky has been a Managing Director with Windsor Private Capital Inc. and its predecessor JJR Capital Corp. Prior to joining Windsor, he was a Vice President at Greenhill & Co., an independent global investment banking firm, listed on the NYSE, focused on mergers & acquisitions and financial restructuring from March 2006 to May 2008. Prior to joining Greenhill, Mr. Kupinsky held the positions of Vice President of Corporate Development and General Counsel at Minacs Worldwide Inc., a publicly traded company on the TSX from July 2002 to February 2005. Mr. Kupinsky began his career practicing corporate and securities law at Torys LLP in Toronto (from 1997 to 1999) and was also an investment banking associate at Houlihan Lokey Howard & Zukin from 1999 to 2002. He holds a joint MBA and JD degree from the Schulich School of Business and Osgoode Hall Law School at York University. Mr. Kupinsky is currently a director of Atlas Financial Holdings Inc. where he chairs the audit committee. Mr. Kupinsky has served as a director of companies on the TSX and on the TSXV, including having served as a director of Xceed Mortgage Corporation from May 2012 through July 2013 when the sale of Xceed to MCAN Mortgage Corporation was completed.Filing StatementIn connection with the Transaction and pursuant to TSXV requirements, Mercari has filed a filing statement dated December 13, 2013 (the "Filing Statement") on SEDAR (.sedar.com). The Filing Statement contains details regarding the Transaction, the Amalgamation, the Private Placement, Mercari, Concordia and the Resulting Issuer.SponsorConcordia has engaged GMP Securities L.P. and Canaccord Genuity Corp. (together, the "Sponsors") as its sponsors in connection with the listing of the common shares of the Resulting Issuer on the TSX.Completion of the Transaction is subject to a number of conditions including, but not limited to, TSXV acceptance and, if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.Investors are cautioned that, except as disclosed in the filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in securities of a capital pool company should be considered highly speculative.The TSXV has in no way passed upon the merits of the Transaction and has neither approved nor disapproved the content of this press release.The Sponsors, subject to completion of satisfactory due diligence, have agreed to act as sponsors in connection with the listing of the common shares of the Resulting Issuer on the TSX. An agreement to sponsor should not be construed as any assurance with respect to the merits of the transaction or the likelihood of completion.* * *This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction.ANY SECURITIES REFERRED TO HEREIN WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 (THE "1933 ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO A U.S. PERSON IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE 1933 ACT.Notice regarding forward-looking statements:This release includes forward-looking statements regarding Mercari, Concordia, and their respective businesses, which may include, but is not limited to, statements with respect to the completion of the Transaction, the Private Placement and the acquisition of Pinnacle, the terms on which the Transaction, Private Placement and acquisition of Pinnacle are intended to be completed, the use of the net proceeds from the Private Placement, the ability to obtain regulatory and shareholder approvals and other factors. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, including completion of the Transaction, the Private Placement and the acquisition of Pinnacle, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the pharmaceutical industry, failure to obtain regulatory or shareholder approvals, economic factors, the equity markets generally and risks associated with growth and competition. Although Mercari and Concordia have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Mercari and Concordia undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.Mercari Acquisition Corp.CONTACT: Elena Masters, Director of Mercari Acquisition Corp. at 416 972 9993.迷你倉

明年LED照明滲透率上看20％，mini storageLED近期成為市場當紅炸子雞。身兼億光（2393）董事長、晶電（2448）副董事長的葉寅夫昨（13）日指出，LED市場成長看好，以上游的晶片廠而言，晶電受惠程度高於大陸業者。而有下游業者評估，從明年國際前三大照明廠競相推出新品，承接歐美OEM訂單的台廠將得利。 業界預期，明年LED照明滲透率將達20％，後年甚至有機會上看30％。葉寅夫指出，就LED晶片鏈來看，大陸一線廠向台灣產業借將，使大陸一線廠技術與台灣差距已經不大，但是晶電還是享有較高的品牌知名度，他認為晶電受惠程度將高於大陸廠。葉寅夫指出，明年封裝廠除了衝量之外，成本控制也相當重要，掌握成本與通路是明年的關鍵。億光旗下100％子公司億光固態照明今年台灣區營收達10億元，明年預計跳升至20億元，出貨量則可望大增1.5倍，該公司資本額為4億元，是少迷你倉橫跨商用照明、特殊照明、工程標案的照明廠。由於布建通路相當燒錢，不過從明年開始，億光固態照明在台灣就有機會進入獲利階段。 另有下游業者指出，明年LED照明滲透率爬升時，國際前三大照明廠歐司朗、飛利浦和GE一定會推出低價的照明產品，台灣承接歐美OEM相關訂單的廠商會先獲利。 業者強調，台系品牌明年則處於衝量階段，且必須先經過一段犧牲利潤的陣痛期，把量刺激出來，因此明年受惠程度會落後OEM廠。業者也坦言，明年照明滲透率雖有機會大幅提升，但是消化晶片產能的主力還是背光源，以目前背光源滲透率高達95％來看，晶片產能閒置的情況會有所改善，但恐怕還是呈現供過於求狀態。 LED族群今年以來沉澱已久，挾其籌碼乾淨、低價、低本益比優勢，類股強勢表態，昨日龍頭股億光觸及漲停，創下波段新高價63.2元，中低價位的東貝、佰鴻、泰谷、湯石、光鋐盤中均見漲停。文件倉

迷你倉 本報訊筆者從中國鐵路總公司瞭解到，鐵路部門的官方手機購票客戶端———“鐵路12306”12月8日上線試運行，向廣大旅客提供列車信息查詢、購票等服務。“鐵路12306”應用圖標為藍白底色，上方為紅色的中國鐵路路徽，路徽下方標有“中國鐵路”字樣。“鐵路12306”免費供旅客下載使用。使用安卓系統的手機用戶可直接從.1 2306.cn網站下載，使用蘋果手機的用戶可從蘋果應用商店“APPSTORE”下載。試運行期間，如遇到購票不暢等問題，請廣大旅客諒解，並及時選擇其它方式購票，以免耽誤您的行程。(孫雅彬)自存倉

利基型記憶體IC設計廠鈺創（5351）推出手勢與體感辨識單晶片產品，迷你倉最平不但可應用在智慧電視、遊戲機、筆電等大型產品，目前更瞄準穿戴式裝置商機。另外，鈺創本月也開始量產USB供輸電控制晶片，預計明年下半年放量出貨。鈺創的手勢與體感辨識單晶片，搭配兩顆CMOS影像感測晶片，組成3D深度影像感測模組。雙鏡頭同步擷取畫面，在高速運算分析後，可即時輸出物件的深度圖像，再透過USB 3.0傳輸介面等傳送到主機，而且優點在於不需紅外線及雷射光源，只需要環境光源即可操作，在室內或戶外皆能運作。鈺創的手勢與體感辨識單晶片已開始出貨，鈺創表示，目前正與多家廠商接洽合作，將晶片嵌入穿戴式裝置，並與以色列、歐迷你倉、美國與俄羅斯等地的軟體業者合作，希望創造更多應用可能性，相關發展應用情境例如戴智慧眼鏡時，使用者可以懸空手勢撥打電話等。另外，鈺創推出USB供輸電控制晶片，讓USB充電功率從10瓦擴大到100瓦，而且還可以雙向供電，同時傳輸資料。例如顯示器與筆電均配置USB供輸電控制晶片，可透過USB介面傳輸線，筆電內的資料在顯示器上播出，顯示器也可供給筆電所需電力，筆電不需另有電源也可操作。鈺創強調，USB供電從2.5瓦到100瓦設備都可充電，且使用相同接口與標準，不會因為不相容而導致設備燒毀。初期看來，導入USB供輸電控制晶片的業者，以顯示器與筆電客戶的進度較快，目前各已有一家廠商採用鈺創的產品。mini storage

通訊應用程式LINE人氣扶搖直上，迷你倉金融業也不錯過。繼新光、南山等老牌壽險公司推出免費貼圖下載後，擁有高人氣的台灣人壽「台灣阿龍」也推出八款LINE貼圖，而南山人壽貼圖則已在11日截止下載。LINE全台用戶日前正式突破1,700萬戶，占全台人口的七成四，已成為台灣通訊軟體的第一名，凸顯台灣人對LINE的依賴程度及社交方式的改變，各保險公司紛紛推出LINE貼圖，拉近與年輕族群的距離，行銷自身的保險商品。在壽險品牌中，一向具有高人氣的台灣人壽企業吉祥物「台灣阿龍」，10日推出免費下載LINE貼圖。台灣人壽表示，特別選在聖誕節及新年即將到來的時刻，「龍」重推出八款可愛討喜的「阿龍LINE貼圖─樂活篇」，希望傳達熱情陽光的self storage象，並結合保險守護大家平安健康及壽險業務員，努力打拚的積極態度，讓阿龍溫暖歡樂的形象深植人心。「台灣阿龍」是在2004年8月以一首「希望每天都是星期天，無憂無慮快樂去聊天~」阿龍主題曲紅遍大街小巷，人人琅琅上口，帶動人氣紅不讓，也為台灣人壽品牌翻新。因廣受大小朋友喜愛，多年來推出不計其數的周邊商品，不僅是台灣人壽最佳代言人，也是與保戶、消費者互動的最佳橋樑。壽險業推出LINE貼圖由新光人壽開先鋒，已經停止下載，但累計下載量高達550萬次，貼圖使用次數則已達8,700萬次，在金融業傲視群倫。南山人壽上個月也推出以客服人員形象的LINE貼圖，於11日截止下載；目前下載次數已超過500萬次，貼圖使用次數約2,000萬次。迷利倉

【本報訊】就橫琴新區二線監管設施於日前竣工，self storage橫琴新區管委會主任牛敬昨來澳出席港珠澳大橋研討會時接受傳媒採訪，他表示澳門車輛進入橫琴新區未有具體時間表，但指出管委會有一些技術性成果，要與澳門特區政府溝通，而一切均需待國家完成驗收才能加快實施，預計年底前會有驗收消息。澳車進橫琴待封關運作加快實施根據國務院關於橫琴創新通關的批覆，橫琴與澳門之間的口岸將設定為「一線」，橫琴與內地之間設定為「二線」。橫琴新區二線監管設施包括二線通道設施、環島電子圍網迷你倉電子聯網等，已於本月8日竣工。牛敬表示，整個橫琴新區二線監管設施全部建設完成，順利完工，廣東省人民政府正式向中央政府呈交報告，要求國家有關部委積極協調，盡快安排驗收。他說，希望盡快進入驗收程序，預計會在年底前有驗收消息。對於能否在明年上半年實現澳門車輛進入橫琴？牛敬坦言，一切均需等待橫琴新區完成二線驗收，實行封關運作後才能加快實施。他指出：管委會正進行深入研究，準備數個方案，並有一些技術性成果，而且亦要與澳門特區政府溝通，現時未有具體時間表。迷你倉樂器

【特訊】第五十六屆亞太影展昨日在澳門開幕，迷你倉籌委會召集人陳澤武受訪時表示，只要有足夠的投入及政策推動，澳門電影業具條件發展成為一個文化產業。 陳澤武表示，澳門有一批有志之士為文創產業打拼，但大都較為疏散，現時特區政府設立文化產業基金，為文創工作者提供協助，加上港澳兩地關係密切，香港電影業界豐富的經驗，為澳門提供借鑑，推動澳門電文件倉業的發展，他認為只要有足夠的投入及政策推動，如制定長遠的人才培養計劃、提供專業培訓等，澳門電影業有條件發展成為一個文化產業。他又稱，今次亞太影展這一國際影壇盛事再次在澳門舉行，吸引國際目光聚焦澳門，為澳門作一次很好的宣傳推廣，他認為舉辦國際性的大型文化盛事，對推動澳門旅遊文化產業的發展有積極意義，有助提高澳門國際知名度。獎等活動。存倉

儲存 繼《May姐有請》後，無線推出由因黃淑儀（GiGi姐）主持的美食節目《吾淑吾食》接棒。在首集推出的“減壓餐”，亦受到�多藝人和觀�捧場，成功扭轉《May姐有請》的頹勢。據知，節目每集均有不同的主題，如壓力、美容、老人問題等，GiGi姐會為不同嘉賓度身定造餐單。此外，節目更邀請了專業營養師及中醫師詳細講解食材的營養、對人體的益處，讓嘉賓與觀�一起瞭解“醫食同源”的道理。看得出節目是用心製作，難怪好評如潮。迷你倉

今年台中資訊月主題區的新面孔，儲存由行政院科技會報辦公室委託資策會規劃執行「國家創新館」，跳脫傳統資訊月科技的框架，匯集台灣社會各角落不同的創意及創新成果，呈現出最具活力的民間力量，充滿濃濃台灣味，讓民眾從數位科技的氛圍，進入屬於「台灣味」的社會創新，是一個值得參觀和細細品嚐的科技人文創新饗宴。好的創新，能促進產業轉型；好的創意，能解決問題；好的故事，能激勵人心。「國家創新館」以「數位匯流」作為活動主題，延伸出規劃的《主題館》呈現的就是行政院在推動的數位匯流建設所匯集、合流出的產業創意與價值；《社會創新館》挖掘出臺灣在地的社會創新力量，以創意用心的動力，來影響整個社會。《微電影館》以影像挖掘出社會創新好故事，促成本土創意能在華人影音平台奠定優良的臺灣品牌形象。數位匯流 三way新世代走進國家創新館，首先映入眼簾的就是《數way匯流主題館》，配合行政院科技會報辦公室推動國家資通訊建設，以三個佇立在國家創新館門口巨大鮮明的電腦(網路)、電話(電信)及電視(廣電)模型公仔設計，代表著國內三網(Way)由於科技進步和法規開放後，如今三網(Way)匯流彼此競爭合作，無論使用何種裝置介面，隨時隨地都能打電話、看電視、上網路，帶給民眾更多的便利性，而這就是數位匯流。《數way匯流主題館》邀請國內包括中華電信、TBC台灣寬頻通訊、TOP台灣數位光訊科技、VeeTIME威達雲端電訊參與，共同展示數位匯流融合的網路、技術與服務。接著進入《數味匯流社會創新館》在臺灣社會各角落萌生非常多創新點子，運用新的方法或科技來解決社會問題、讓這個社會變得更美好。因此國家創新館徵選全國各角落默默耕耘的社會創新成果，以及各領域之創新應用服務的成功典範作為展示，包括南迴醫療方舟教室、崔媽媽基金會、家扶基金會、責任旅行、回歸單純的旅人創意行動、四方報、上下游新聞市集、喜願共合國、直接與農夫買、南澳自然田、248農學市集等結合國內公益團體、社會企業、社會關懷、農業創新等蘊涵了東方文化深度與當代創意思維的社會創新內容。另外特別邀請佛教迷你倉濟基金會展出最具人情味的「慈濟慈悲科技」，身為宗教團體的慈濟，透過創新思維與具體行動，走出一條慈悲與智慧的圓融之路，是華人文化的社會最佳實踐。為因應不同災難及緊急援助物資需求，以創新的思惟成立「慈濟國際人道援助會」，秉持證嚴上人「愛護地球、悲憫眾生」的心念，投入研發賑災物資，以「食、衣、住、行、資訊及研發」為架構，成立「食品、衣著、住屋、運輸、資通訊及綠能」等六組，此次將在「國家創新館」中展出的「急難組合屋」、「綠色傳奇－慈濟環保毛毯」、「災難中的溫暖－香積飯」、「將惡水淨化為生命之水－急難救助淨水艇」等成果展示，了解該組織在社會需求與科技研發之間創新思維。數微匯流 百大創新微視界最後進入《數微匯流微電影館》，2013年是「微新運動元年」，充分反映智慧行手機、平板電腦等行動載具蓬勃的發展。今年舉辦的第一屆「臺灣微電影節選拔活動」，以「社會創新」為主題，鼓勵發掘臺灣各地的創新故事，未來也將在4G的基礎上建置創作平台，培養影視人才，更透過此平台讓「創意臺灣」的品牌效應全球發酵，讓世界看見臺灣！在這裡可以觀賞「臺灣微電影節選拔」得獎作品，與民眾分享素人和新銳導演的微電影，一起感受和體驗臺灣美好的社會創新故事。「國家創新館」的創意成果，最後將會出版一套「臺灣百大社會創新案例酷卡」，這是歷經半年由「臺灣百大社會創新徵選活動」所精萃出100多個代表臺灣社會創新案例匯集而成的創意出版品，每張創意的酷卡主角，都是在各行各業中勤勞、務實、具十足創意的臺灣人民，此次將在「國家創新館」開放五折預購。另外在「國家創新館」展覽期間，參觀民眾只要持手機在【Taiwan IDEAS國家創新力提升計畫】臉書上按讚，即可現場參加抽獎，兌換精美禮物。現場還能品嘗慈濟香積飯等活動。(資策會廣告)資訊月展訊更多活動詳情資訊可洽：官方網站.taiwanideas.com/innomonth臉書粉絲專頁https://.facebook.com/pages/Taiwan-Ideas-國家創新力提升計畫/307138256085775儲存倉